Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Hyperphagia 2Short Bowel Syndrome 1Pena Shokeir syndrome, type 1 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × soybean oil, phospholipid emulsion × Clear all
NCT04555044 2023-12-27

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Baxter Healthcare Corporation

Phase 4 Completed
101 enrolled 29 charts

Pena Shokeir syndrome, type 1, Hyperphagia, Short Bowel Syndrome

NCT00292279 2008-05-14

The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients

Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd

Phase 3 Completed
206 enrolled

Hyperphagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡